PL3481865T3 - Mutanty fc o ulepszonej aktywności funkcjonalnej - Google Patents

Mutanty fc o ulepszonej aktywności funkcjonalnej

Info

Publication number: PL3481865T3
Authority: PL; Poland
Prior art keywords: mutants; functional activity; improved functional; improved; activity
Prior art date: 2016-07-06

Application number

PL17739229.7T

Other languages

English (en)

Inventor

Céline MONNET

Original Assignee

Laboratoire Français Du Fractionnement Et Des Biotechnologies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-06

Filing date

2017-07-05

Publication date

2024-02-19

2017-07-05 Application filed by Laboratoire Français Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Français Du Fractionnement Et Des Biotechnologies

2024-02-19 Publication of PL3481865T3 publication Critical patent/PL3481865T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL17739229.7T 2016-07-06 2017-07-05 Mutanty fc o ulepszonej aktywności funkcjonalnej PL3481865T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR1656463A FR3053688B1 (fr)	2016-07-06	2016-07-06	Mutants fc a activite fonctionnelle amelioree
PCT/EP2017/066791 WO2018007453A1 (fr)	2016-07-06	2017-07-05	Mutants fc a activite fonctionnelle amelioree

Publications (1)

Publication Number	Publication Date
PL3481865T3 true PL3481865T3 (pl)	2024-02-19

Family

ID=57583168

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17739229.7T PL3481865T3 (pl)	2016-07-06	2017-07-05	Mutanty fc o ulepszonej aktywności funkcjonalnej

Country Status (8)

Country	Link
US (1)	US11814438B2 (pl)
EP (2)	EP3481865B1 (pl)
CA (1)	CA3029971A1 (pl)
DK (1)	DK3481865T5 (pl)
ES (1)	ES2965076T3 (pl)
FR (1)	FR3053688B1 (pl)
PL (1)	PL3481865T3 (pl)
WO (1)	WO2018007453A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR3075200B1 (fr)	2017-12-15	2022-12-23	Lab Francais Du Fractionnement	Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
EP3805400A4 (en) *	2018-06-04	2022-06-29	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule showing changed half-life in cytoplasm
WO2021220218A1 (en) *	2020-05-01	2021-11-04	Novartis Ag	Immunoglobulin variants
US12227593B2 (en) *	2020-05-20	2025-02-18	Janssen Biotech, Inc.	Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase
US12030945B2 (en)	2022-10-25	2024-07-09	Seismic Therapeutic, Inc.	Variant IgG Fc polypeptides and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2807767B1 (fr)	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-d
US20040002587A1 (en) *	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
US8093357B2 (en)	2002-03-01	2012-01-10	Xencor, Inc.	Optimized Fc variants and methods for their generation
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
EP2233500A1 (en) *	2009-03-20	2010-09-29	LFB Biotechnologies	Optimized Fc variants
WO2012125850A1 (en) *	2011-03-16	2012-09-20	Amgen Inc.	Fc variants
JP6774164B2 (ja)	2012-08-24	2020-10-21	中外製薬株式会社	マウスＦｃγＲＩＩ特異的Ｆｃ抗体
UY35148A (es) *	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
FR3003171B1 (fr) *	2013-03-15	2015-04-10	Lab Francais Du Fractionnement	Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

2016
- 2016-07-06 FR FR1656463A patent/FR3053688B1/fr active Active
2017
- 2017-07-05 ES ES17739229T patent/ES2965076T3/es active Active
- 2017-07-05 WO PCT/EP2017/066791 patent/WO2018007453A1/fr not_active Ceased
- 2017-07-05 PL PL17739229.7T patent/PL3481865T3/pl unknown
- 2017-07-05 US US16/315,356 patent/US11814438B2/en active Active
- 2017-07-05 EP EP17739229.7A patent/EP3481865B1/fr active Active
- 2017-07-05 CA CA3029971A patent/CA3029971A1/fr active Pending
- 2017-07-05 DK DK17739229.7T patent/DK3481865T5/da active
- 2017-07-05 EP EP23183322.9A patent/EP4273163A3/fr active Pending

Also Published As

Publication number	Publication date
ES2965076T3 (es)	2024-04-11
DK3481865T5 (da)	2024-09-02
DK3481865T3 (da)	2023-12-11
EP4273163A2 (fr)	2023-11-08
EP3481865B1 (fr)	2023-09-06
FR3053688B1 (fr)	2026-05-01
US20190309085A1 (en)	2019-10-10
EP3481865A1 (fr)	2019-05-15
EP4273163A3 (fr)	2024-04-03
CA3029971A1 (fr)	2018-01-11
US11814438B2 (en)	2023-11-14
FR3053688A1 (fr)	2018-01-12
WO2018007453A1 (fr)	2018-01-11

Publication	Publication Date	Title
PL3292145T3 (pl)	2025-06-09	Mutanty fc ze zmodyfikowaną aktywnością funkcjonalną
ZA201704556B (en)	2018-11-28	Picolinamides with fungicidal activity
GB2557693C (en)	2021-09-29	Headgear assemblies and interface assemblies with headgear
GB201406968D0 (en)	2014-06-04	Deletion mutants
GB201616363D0 (en)	2016-11-09	Dust extractor with flat back
PL3674004T3 (pl)	2022-09-19	Zespół dyszy z powierzchnią samoczyszczącą
IL249511B (en)	2019-11-28	Novel p450–bm3 variants with enhanced activity
SG11201606004PA (en)	2016-08-30	Upper dome with injection assembly
AP2016009385A0 (en)	2016-08-31	Lancet assembly
GB201622086D0 (en)	2017-02-08	Biocontrol organism
PL3548758T3 (pl)	2022-05-16	Zespół ślizgowy
IL256441B (en)	2020-02-27	New p450–bm3 variants with enhanced activity
DK3481865T5 (da)	2024-09-02	Fc-mutanter med forbedret funktionel aktivitet
PL3303243T3 (pl)	2020-03-31	Lustro o ulepszonej trwałości
GB201608056D0 (en)	2016-06-22	Improved analysis with preliminary survey
HUE047553T2 (hu)	2020-04-28	Dextrán-szaccharáz aktivitású protein és alkalmazásai
GB201420952D0 (en)	2015-01-07	Head unit with interchangeble functional bezel
PT3430031T (pt)	2022-01-24	Péptidos com atividade anticancerígena
PL3383851T3 (pl)	2022-01-10	Pochodne dekstrorfanu o stłumionej nerwowej aktywności ośrodkowej
EP3279323A4 (en)	2018-10-24	Amadoriase having improved specific activity
GB201510804D0 (en)	2015-08-05	Armrest assembly
ZA201705324B (en)	2020-12-23	Carbon activity analyser
GB2546297B (en)	2020-10-07	Retaining structure assembly
GB201416411D0 (en)	2014-10-29	Trenchcover with retainer
GB201520417D0 (en)	2016-01-06	Trenchcover with retainer